Introduction
============

Type 2 diabetes mellitus (T2DM) is a rapidly growing problem in the industrialized world. In the United States, it is estimated that 8.3% of the population has diabetes \[[@B1]\]. T2DM results from a combination of insulin resistance and pancreatic beta-cell dysfunction \[[@B2]\]. The development of T2DM depends on both genetic and environmental risk factors \[[@B3]\]. The major environmental risk factor for the development of insulin resistance and T2DM is obesity. Increased white adipose tissue (WAT) mass during obesity causes a variety of problems related to the development of insulin resistance. It is now established that WAT acts as a lipid metabolism modulator as well as an endocrine organ \[[@B4]\].

The secreted proteins of adipose tissue, known as adipocytokines, can act in a paracrine or endocrine manner to modulate a variety of processes such as inflammation and whole-body energy homeostasis. During obesity, adipocytokine secretion is altered, which can lead to the development of whole-body insulin resistance and T2DM \[[@B5],[@B6]\]. Although many adipocytokines have been identified using methods such as mass spectrometry-based proteomics, the alteration in the adipose tissue secretome for normal vs. insulin resistant human adipose tissue has not been well-defined \[[@B7]\]. Several adipocytokines identified in rodents have different expression patterns in humans highlighting the need for quantitative proteomic studies in human adipose tissue \[[@B8],[@B9]\]. To achieve a more physiological representation of the adipose tissue secretome, we use primary human pre-adipocytes derived from human adipose tissue rather than an adipocyte cell line \[[@B10]\].

The regulation of adipocytokine expression during insulin resistance is still unclear in many cases. One possible way for cells to sense nutrient abundance and modulate insulin sensitivity and adipocytokine expression is through the hexosamine biosynthetic pathway (HBP). Excessive flux through the HBP results in insulin resistance, thereby limiting the amount of glucose that enters the cell and the resulting toxicity \[[@B11],[@B12]\]. Flux through the HBP also modulates the expression of several adipocytokines \[[@B13]-[@B16]\]. The final product of the HBP is UDP-GlcNAc, which is the sugar donor for the enzyme O-GlcNAc transferase (OGT) that adds the O-linked *β*-N-acetylglucosamine (O-GlcNAc) modification onto the serine and threonine residues of nucleocytosolic proteins \[[@B17],[@B18]\]. It has been shown in multiple systems that the elevation of O-GlcNAc levels is sufficient to cause insulin resistance \[[@B19]-[@B24]\]. Furthermore, the overexpression of OGT in the peripheral tissues of mice results in both glucose disposal defects and hyperleptinemia providing further evidence that the O-GlcNAc modification causes insulin resistance and the dysregulation of adipocytokine expression \[[@B21]\]. We have previously characterized and quantified the secretome of rodent adipocytes during insulin resistance generated by either directly or indirectly modulating O-GlcNAc levels \[[@B25]\]. We use a similar approach in this study. Insulin resistance is induced in primary human adipocytes by either the classical method of chronic hyperinsulinemia and hyperglycemia or by directly elevating O-GlcNAc levels using O-GlcNAcase (OGA) pharmacological inhibitors. To identify and quantify the secretome we use a proteomic approach with reverse phase (RP) liquid chromatography-nanospray-tandem mass spectrometry (LC-NS-MS/MS). We identify a total of 190 secreted proteins from primary human adipocytes. We compare the relative abundance of the adipocytokines during insulin responsive versus insulin resistant conditions using spectral counts. We report that 20 proteins are upregulated and 4 are downregulated when primary human adipocytes are shifted from insulin sensitive to insulin resistant conditions.

Glycosylation is one of the most common post-translational modifications (PTMs) of proteins, especially of secreted proteins \[[@B26]-[@B34]\]. In certain disease states, the glycome and the enzymes responsible for the glycan complexity can be altered \[[@B35],[@B36]\]. It has been suggested that the increased pool of UDP-GlcNAc during excessive nutrient flux alters glycosyltransferase activity and the degree of N-glycan branching \[[@B37]\]; however, another study reported no change in complex glycosylation during elevated HBP flux \[[@B38]\]. Determining the glycome in different disease states is important for the future identification of structure-function relationships and to discover targets for diagnostic biomarkers \[[@B25],[@B39],[@B40]\]. The glycome of human adipose tissue has not been previously described. Glycan analysis is challenging due to the diversity of possible structures and their low abundance \[[@B35],[@B41]-[@B49]\]. We use several strategies to identify, site-map, and quantify glycans from adipose tissue using mass spectrometry (MS). We characterize a total of 155 N-linked glycans and 29 O-linked glycans using MS/MS spectra by total ion mapping (TIM) scan. Predominant N-linked and O-linked glycans can be quantified by ^13^C isotopic labeling by permethylation using heavy or light iodomethane (^13^CH~3~I and ^12^CH~3~I) and isobaric pairs of iodomethane (^13^CH~3~I or ^12^CH~2~DI) (48, 49). A total of 48 N-linked glycans and 12 O-linked glycans are compared between the insulin responsive condition and both insulin resistance conditions by calculating the ^13^C/^12^C ratios from the sum of peak areas and from non-labeled prevalence rates. We also identify 91 N-glycosylation sites derived from 51 secreted proteins using the PNGase F digestion in ^18^O water using a parent mass list method.

Herein, we describe the secretome and glycome of primary human adipocytes during insulin sensitive and insulin resistant condition. Given the important physiological roles of adipocytokines in maintaining whole-body energy homeostasis, the characterization of the primary human adipocyte secretome during insulin resistance could provide novel markers and/or therapeutic targets for the onset of insulin resistance.

Experimental procedures
=======================

Tissue culture and conditioned cell treatments
----------------------------------------------

Cryopreserved human subcutaneous preadipocytes (number of donors: 6--7, gender of donors: female, average age: 39, and average BMI: 27.32) were purchased from Zen-Bio, Inc. (Research Triangle Park, NC). The adipose tissue culture protocols of the maintenance and differentiation from preadipocytes to adipocytes were based on Zen-Bio instruction manual (ZBM0001.01). Briefly approximately 6.7 × 10^5^ cells were cultured in a T-75 cm^2^ culture flask using preadipocyte medium (PM-1, Zen-Bio, Inc.), under a humidified atmosphere containing 5% CO~2~ in air at 37°C until they were 85-90% confluent, and then were trypsinized for 5 minutes at 37°C. After neutralization and centrifugation steps, the cell pellet was resuspended in PM-1 and seeded at an average density of 2.67 × 10^4^ cells/cm^2^ in 10-cm cell culture dishes for differentiation. 2 days after the cells reached confluence (referred to as day 0), the medium was replaced with adipocyte differentiation medium (DM-2, Zen-Bio, Inc.). On day 7, the DM-2 was removed and the cells were maintained in adipocyte maintenance medium (AM-1, Zen-Bio, Inc.). The medium was changed every 3 days. On day 15, at which the majority of the cells contained large lipid droplets, the AM-1 medium was replaced with low glucose DMEM (Cellgro, Mediatech, Inc.) containing 10% FBS (GIBCO, Invitrogen) and antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin (P/S), Cellgro, Mediatech, Inc.). The medium was changed every 2 days until treatments were applied. On day 20, adipocytes were treated with different conditions, either (1) low glucose (LG) (LG, DMEM containing 10% FBS and P/S), (2) insulin (100 nM, human, Roche) in high glucose (HG + INS) (HG, DMEM containing 10% FBS and P/S), (3) PUGNAc (100 μM, TRC, Inc.) in low glucose (LG + PUGNAc) (LG, DMEM containing 10% FBS and P/S), or (4) GlcNAcstatin (20 nM, kind gift from Dr. Daan van Aalten) in low glucose (LG + PUGNAc) (LG, DMEM containing 10% FBS and P/S). After the first 24 h of incubation, the cells were washed five times (for mass spectrometry analysis) or 3 times (for immunoblotting) with low or high glucose serum-free DMEM without antibiotics and incubated for 15 min during the last rinse. After the final wash, the treatment conditions were added as above except no serum was added and the HG + INS treatment was changed to 1nM Insulin. The cells and media were harvested after 16 h of incubation.

Secreted protein sample preparation
-----------------------------------

The conditioned media was harvested with extreme care not to disrupt underlying cells and then centrifuged once at 1800 rpm, at 4°C for 7 min. The supernatant was filtered using 1 μm syringe filters (PALL). The samples were then centrifuged again at 30000 × *g*, at 4°C for 30 min. The samples were then transferred to equilibrated spin columns (Centriprep YM-3, Amicon, Millipore) and buffer-exchanged at 2800 × *g*, at 4°C into 40 mM ammonium bicarbonate (NH~4~HCO~3~) in the presence of 1 mM dithiothreitol (DTT, Fisher Scientific) and concentrated. The samples were either quantified and prepared for immunoblotting or were denatured with 1 M urea (Sigma), reduced with 10 mM DTT for 1 h at 56°C, carboxyamidomethylated with 55 mM iodoacetamide (ICH~2~CONH~2~, Sigma) in the dark for 45 min, and then digested with 4 μg of trypsin (Promega) in 40 mM NH~4~HCO~3~ overnight at 37°C. After digestion, the peptides were acidified with 200 μL of 1% trifluoroacetic acid (TFA). Desalting was subsequently performed with C18 spin columns (Vydac Silica C18, The Nest Group, Inc.) and the resulting peptides were dried down in a Speed Vac and stored at −20°C until analysis. For the subset of samples to be analyzed for N-linked glycosylation, peptides were resuspended in 19 μL of ^18^O water (H~2~^18^O, 95%, Cambridge Isotope Laboratories, Inc.) and 1 μL of N-Glycosidase F (PNGase F, Prozyme) and allowed to incubate for 18 h at 37°C. Peptides were dried back down and resuspended in 50 μL of 40 mM NH~4~HCO~3~, with 1 μg of trypsin for 4 hr, to remove any possible C-terminal incorporation of ^18^O from residual trypsin activity, and then dried down and stored at −20°C until analysis.

Whole cell extracts and western blots
-------------------------------------

After culture medium was removed for secreted proteins analysis, the cell monolayer was washed twice with 10 ml of ice-cold PBS and scraped in the presence of 1 ml PBS plus protease inhibitors. After removing PBS by centrifugation at 6,000 × *g* for 5 min at 4°C, the pellet was snap frozen and stored at −80°C. To prepare lysate for immunoblotting, the pellets were lysed in 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1:100 protease inhibitor cocktail set V, EDTA-free (Calbiochem), and 1 uM PUGNAc. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific) and samples were boiled in Laemli sample buffer. The immunoblots were performed essentially as described \[[@B50]\] using CTD 110.6 (for O-GlcNAc modified proteins) and ERK-2 (as a positive control for loading) antibodies. For secreted protein immunoblotting, the media concentration was quantified using the Bradford method and verified by Coomassie staining. Equal amounts of protein were separated by SDS-PAGE with Tris--HCl precast minigels (Bio-Rad) and transferred to nitrocellulose membranes for Western blot analysis. After blocking for at least 1 hour, membranes were incubated with the appropriate primary antibody, anti-SPARC (Abcam) or anti-Chitinase-3-like protein 1 (R&D Systems) overnight at 4°C. Membranes were incubated with the appropriate horseradish peroxidase-coupled secondary antibodies for 1 hour, followed by extensive washing and Pierce ECL detection.

Protein extracts for glycan analysis
------------------------------------

After the conditioned media was collected, the adipocytes were immediately washed twice with ice-cold PBS and harvested by scraping for glycan analysis. The cells were centrifuged at 12,000 × *g*, at 4°C for 15 min to remove the supernatant and debris, then snap frozen and stored at −80°C until analysis. After the cell pellets thawed on ice, the samples were subjected to Dounce homogenization in ice-cold 100% methanol. The homogenized samples were delipidated by two solvent extractions using a mixture of chloroform/methanol/water (4:8:3, v/v/v) and rocking for 3 h at room temperature as described previously \[[@B35],[@B40]\]. The emulsion was centrifuged at 2800 × *g* for 15 min at 4°C to remove the supernatant. The pellets were resuspended in an acetone/water (10:1, v/v) mixture and incubated on ice for 15 min for washing. The protein pellets were collected by centrifugation and dried on a heating module at 45°C under a mild nitrogen stream (Reacti-Therm™ and Reacti-Vap™, Pierce). The dried protein powder was weighed and stored at −20°C until analysis.

Preparation of N-linked glycans
-------------------------------

Three mg of the protein powder was resuspended in 200 μL of 40 mM NH~4~HCO~3~ by sonication followed by boiling at 100°C for 5 min. After cooling to room temperature, 25 μL of trypsin (2 mg/mL in 40 mM NH~4~HCO~3~, Sigma) and chymotrypsin (2 mg/mL in 40 mM NH~4~HCO~3~, Sigma) were added. The samples were denatured with 250 μL of 2 M urea in 40 mM NH~4~HCO~3~, leading to a final concentration of 1 M urea, and incubated overnight (18 h) at 37°C. After digestion, the peptide samples were centrifuged and 10 μL of the supernatant was collected for protein quantification. The peptide concentrations were measured using a Pierce BCA Protein Assay Kit (Thermo Scientific). The samples were boiled at 100°C for 5 min and then acidified by adding 500 μL of 10% acetic acid (AcOH) to deactivate proteases. The samples were loaded onto an equilibrated C18 extraction column (BakerBond™, J.T.Baker), washed with 1 mL of 5% AcOH three times, and then eluted stepwise using 1 mL of 20% isopropanol in 5% AcOH, 40% isopropanol in 5% AcOH, and 100% isopropanol. The resulting glycopeptides were dried in a Speed Vac, resuspended in 48 μL 1× PNGase F reaction buffer and 2 μL PNGase F and incubated for 18 h at 37°C. Following PNGase F digestion, released oligosaccharides were separated by the C18 extraction column. The mixture was reconstituted in 5% AcOH and loaded onto an equilibrated C18 extraction column. The N-linked oligosaccharides were eluted using 1 mL of 5% AcOH three times and then collected and dried using a Speed Vac for subsequent permethylation.

Preparation of O-linked glycans
-------------------------------

O-linked oligosaccharides were released by reductive *β*-elimination then purified by a cation exchange resin. Three mg of delipidated protein powder was weighed and transferred into a clean glass tube. 500 μL of 50 mM sodium hydroxide (NaOH) and 500 μL of alkaline borohydride solution (a mixture of 2 M sodium borohydride (NaBH~4~, Sigma-Aldrich) in 50 mM NaOH leading to a final concentration of 1 M NaBH~4~) were added to the tube. The mixture was incubated for 16 h at 45°C on the heating block and the reaction was stopped by the addition of 10% AcOH with vortexing. The acidified mixture was loaded onto an equilibrated cation exchange resin cartridge (AG 50 W-X8, Bio-Rad) with 5% AcOH. O-linked glycans were eluted with 6 mL of 5% AcOH and then dried in a Speed Vac. The sample was resuspended in 1 mL methanol/glacial acetic acid (9:1, v/v) solution and dried on the heating module at 45°C under a mild nitrogen stream to remove borates for subsequent permethylation.

Permethylation of glycans
-------------------------

To facilitate analysis of oligosaccharides by mass spectrometry, the released oligosaccharide mixtures were permethylated as described previously \[[@B35],[@B39],[@B51]\]. Briefly, glycans were resuspended in 200 μL of anhydrous dimethyl sulfoxide (DMSO, Sigma-Aldrich) and 250 μL of fresh dehydrated NaOH/DMSO reagent (mixture of 50 mg NaOH in 2 mL of anhydrous DMSO). After sonication and vortexing under nitrogen gas, 100 μL of ^12^C or ^13^C-iodomethane (^12^CH~3~I and ^13^CH~3~I, 99% of ^13^C, Sigma-Aldrich) was added and the mixtures were vortexed vigorously for 5 min. 2 mL of distilled water was added to the samples and the excess iodomethane was removed by bubbling with a nitrogen stream. Two mL of dichloromethane (CH~2~Cl~2~, Sigma-Aldrich) was added. After vigorous mixing and phase separation by centrifugation, the upper aqueous layer was removed and discarded. The nonpolar organic phase was then extracted 4 times with distilled water. Dichloromethane was evaporated on the heating module at 45°C with a mild nitrogen stream. The permethylated glycans were dissolved in adjusted volumes (15--30 μL) of 100% methanol according to the results of the protein assay. The ^12^C and ^13^C-labeled permethylated glycans were mixed in the same proportion for each experimental condition before analysis.

Analysis using mass spectrometry
--------------------------------

For proteome analysis of secreted proteins by liquid chromatography tandem mass spectrometry (LC-MS/MS), the peptides were resuspended with 19.5 μL of mobile phase A (0.1% formic acid, FA, in water) and 0.5 μL of mobile phase B (80% acetonitrile, ACN, and 0.1% formic acid in water) and filtered with 0.2 μm filters (Nanosep, PALL). The samples were loaded off-line onto a nanospray tapered capillary column/emitter (360 × 75 × 15 μm, PicoFrit®, New Objective) that was self-packed with C18 reverse phase (RP) resin (8.5 cm, Waters) in a nitrogen pressure bomb for 10 min at 1000 psi (\~5 μL load). The samples were then separated via a 160 min linear gradient of increasing mobile phase B at a flow rate of \~200 nL/min directly into the mass spectrometer. One-dimensional LC-MS/MS analysis was performed using a linear ion trap and an Orbitrap mass spectrometer (LTQ and LTQ Orbitrap XL, Thermo Fisher Scientific Inc., San Jose, CA) equipped with a nanoelectrospray ion source at 2.0 kV capillary voltage and 200°C capillary temperature. For secretome analysis, a full ITMS (Ion trap mass spectrometry) spectrum in positive ion and profile mode was collected at 300--2000 m/z followed by 8 MS/MS events on the 8 most intense peaks with enabled dynamic exclusion using a repeat count of 2, a maximum exclusion list size of 100, and an exclusion duration of 30 s. Each MS/MS scan event was followed by CID (34% normalized collision energy), 0.25 activation Q, and 30.0 ms activation time. For N-liked glycosylation site mapping, a full FTMS (Fourier transform mass spectrometry) spectrum, typically recorded at 60000 resolution in positive ion and profile mode, was acquired at 300--2000 m/z followed by 5 data dependent MS/MS spectra of ITMS on the most intense ion peaks from parent mass list following CID (36% normalized collision energy), 0.25 activation Q, and 30.0 ms activation time. Dynamic exclusion was set at a repeat count of 2, a maximum exclusion list of 100, and an exclusion duration of 60 s.

For glycome analysis by direct infusion nanospray MS, permethylated glycans were dissolved by combining 15 μL of the isotopically mixed sample in 100% methanol plus 35 μL 1 mM NaOH in 50% methanol. They were infused directly into a linear ion trap and an Orbitrap mass spectrometer using a nanospray ion source with a fused-silica emitter (360 × 75 × 30 μm, SilicaTip™, New Objective) at 2.0 kV capillary voltage, 200°C capillary temperature, and a syringe flow rate of 0.4 μL/min. The full ITMS spectra and FTMS spectra, typically recorded at 60000 resolution in positive ion and profile mode, were collected at 400--2000 m/z for 30 s with 5 microscans and 150 maximum injection times (ms). The centroid MS/MS spectra following collision-induced dissociation (CID) were obtained from 400 to 2000 m/z at 34% and 28% normalized collision energy for N- and O-linked glycans, respectively, 0.25 activation Q, and 30.0 ms activation time by total ion mapping (TIM). Parent mass step size and isolation width were set at 2.0 m/z and 2.8 m/z, respectively, for automated MS/MS spectra with TIM scans.

Data analysis
-------------

The resulting proteomic data was searched against a target nonredundant human (*Homo sapiens*, 5-2-07) database including the common contaminants database obtained from the human International Protein Index (IPI) protein sequence database (European Bioinformatics Institute, <ftp://ftp.ebi.ac.uk/pub/databases/IPI>) using the TurboSequest algorithm (BioWorks 3.3.1 SP1, Thermo Fisher Scientific Inc.) \[[@B52],[@B53]\]. It was also searched against a decoy human database to determine statistically relevant peptide identification. DTA files were generated for spectra with a threshold of 15 ions and a TIC of 2e^3^ over a range of \[MH\]^+^ = 600--4000 for only IT data. The SEQUEST parameters were set to allow 2.0 Da (20 ppm for FT) of precursor ion mass tolerance and 0.5 Da of fragment ion tolerance with monoisotopic mass. Only strict tryptic peptides were allowed with up to two missed internal cleavage sites. Dynamic mass increases of 15.99 and 57.02 Da (15.9949 and 57.0215 Da for FT) were allowed for oxidized methionine and alkylated cysteine, respectively. In the cases where sites of N-linked glycosylation were investigated with PNGase F and ^18^O water, a dynamic mass increase of 3.0 Da (2.9883 Da for FT) was allowed for Asn residues \[[@B54]\]. The masses were selected between 300--2000 m/z at each charge state and 7352 total masses were obtained for parent mass list. Each sample was analyzed by four LC-MS/MS runs with different parent mass list up to 2000 because of maximum number of parent masses for FTMS and mass complexity. The results from shotgun method and parent mass list method were combined and filtered at ≥ 0.60 Final Score (Sf). For relative protein quantification, the identified peptides and proteins were statistically validated between the target and decoy database search results, and protein ratios were determined by normalized spectral counts using ProteoIQ 1.1 (Premiere BioSoft). Proteins identified by two peptides were only considered to be statistically significant at less than 1% protein false discovery rate (FDR) using the ProValT algorithm as implemented in ProteoIQ \[[@B55],[@B56]\]. From the results, the subcellular location of secreted proteins was manually determined for each protein from the Human Protein Reference Database (<http://www.hprd.org/>), Information Hyperlinked Over Proteins (iHOP, <http://www.ihop-net.org/UniPub/iHOP/>) and the UniProtKB/Swiss-Prot (<http://www.ebi.ac.uk/uniprot>) databases. The functional categories of secretome were annotated by the Ingenuity Pathways Analysis program (IPA, Ingenuity Systems, Inc.).

The N- and O-linked glycans released from the protein power of adipocytes were analyzed by full MS following permethylation and subsequent MS/MS fragmentations for specific glycan structures. We used GlycoWorkbench (<http://glycomics.ccrc.uga.edu/eurocarb/gwb/home.action>) to facilitate manually interpretation of the glycan structures from the MS/MS spectra by TIM scan. The areas of each isotopic peak were calculated by their Gaussian distribution and then averaged to compare the relative abundance of each glycan between different samples. The ratio of peak areas from isotopic permethylation defined the relative abundance of each glycan.

Results
=======

Insulin resistance and global O-GlcNAc levels in primary human adipocytes
-------------------------------------------------------------------------

Treatment with hyperglycemia and chronic insulin or normoglycemia and the pharmacological OGA inhibitor, PUGNAc, result in the global elevation of O***-***GlcNAc modified nucleocytosolic proteins and insulin resistance in rodent adipocytes \[[@B19],[@B57]\]. We tested these conditions as well as treatment with a more specific OGA inhibitor, GlcNAcstatin, in primary human adipocytes \[[@B58]\]. Cryopreserved human preadipocytes were expanded and differentiated into mature adipocytes before treatment as described in *Materials and Methods*. Figure [1](#F1){ref-type="fig"} shows that when compared to normoglycemia (LG), treatment with OGA inhibitors (LG + PUGNAc or LG + GlcNAcstatin) or treatment with hyperglycemia and hyperinsulinemia (HG + INS) raises global O-GlcNAc levels as measure by immunoblotting with an O-GlcNAc specific antibody. In a previous study using rodent adipocytes, we characterized and quantified the secretome and glycome during insulin sensitive and insulin resistant conditions induced by indirectly (HG + INS) or directly (LG + PUGNAc) modulating O-GlcNAc levels. We found that many secreted proteins were up or down-regulated upon the induction of insulin resistance. Here we took a parallel approach to ask the same question using primary human adipocytes. As shown in Figure [2](#F2){ref-type="fig"}, after treatment both the cells and conditioned media were harvested. Before the final 16 hour serum-free treatment incubation, the cells were washed five times with serum-free media to remove any traces of serum. This greatly reduced the complexity of the conditioned media. The conditioned media was buffer exchanged and concentrated before being processed for analysis by LC-MS/MS. Cells were collected and delipidated as in *Materials and Methods*. Protein was digested and prepared for either N-glycan or O-glycan analysis (Figure [2](#F2){ref-type="fig"}).

![**Detection of O-GlcNAc levels in primary human adipocytes.** Global O-GlcNAc levels are elevated in three insulin resistant conditions generated by low glucose plus PUGNAc (LG + PUGNAc), low glucose plus GlcNAcstatin (LG + GlcNAcstatin), or high glucose plus chronic insulin exposure (HG + INS).](1559-0275-11-20-1){#F1}

![**Schematic flow diagram of the experimental procedure. (A)** Primary human adipocytes are treated with insulin responsive (LG, normoglycemic) or two insulin resistance generating conditions (HG + INS and LG + PUGNAc). **(B)** Identification and quantification of the secretory proteome and N-linked glycosylation site-mapping from the conditioned media of treated primary human adipocytes **(C)** Characterization and quantification of N- and O-linked glycans from a whole protein extract of treated primary human adipocytes.](1559-0275-11-20-2){#F2}

Characterization of the primary human adipose tissue secretome by LC-MS/MS
--------------------------------------------------------------------------

The mass spectra from 24 mass spectrometric analyses were searched against a target nonredundant human database as well as a decoy human database using SEQUEST. Proteins identified by at least two non-redundant peptides with less than a 1% FDR were identified using ProteoIQ. Secreted proteins were manually determined by a reference search as described in *Materials and Methods*. Using these criteria, a total of 190 secreted proteins were identified. Table [1](#T1){ref-type="table"} shows the complete list of the 173 secreted proteins identified by at least 2 unique peptides. 17 of the secreted proteins identified based on a single peptide are presented in Supplemental Table [1](#T1){ref-type="table"} (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Figure [3](#F3){ref-type="fig"} shows the proportion of the secretome in each of the 9 main functional categories assigned by Ingenuity Pathways Analysis. The most highly represented categories are enzyme, peptidase, and other protein.

###### 

Total secreted proteins from human dispose tissue by LC-MS/MS

   **No.**   **Protein ID**                     **Identifed proteins**                     **Subcellular location**^**a**^
  --------- ---------------- ------------------------------------------------------------ ---------------------------------
      1          Q92484            Acid sphingomyelinase-like phosphodiesterase 3a                  Extracellular
      2          P07108                        Acyl-CoA-binding protein                               Cytoplasm
      3          Q8IUX7                  Adipocyte enhancer-binding protein 1                         Membrane
      4          P01023                         Alpha-2-macroglobulin                                  Nucleus
      5          P06733                             Alpha-enolase                                   Extracellular
      6          P15144                            Aminopeptidase N                                   Cytoplasm
      7          P01019                            Angiotensinogen                                    Membrane
      8          P07355                               Annexin A2                                    Extracellular
      9          P08758                               Annexin A5                                      Membrane
     10          Q8NCW5                   Apolipoprotein A-I binding protein                        Extracellular
     11          P05090                            Apolipoprotein D                                 Extracellular
     12          P02649                            Apolipoprotein E                                 Extracellular
     13          P15289                            Arylsulfatase A                                    Cytoplasm
     14          P61769                          Beta-2-microglobulin                                 Membrane
     15          P21810                                Biglycan                                     Extracellular
     16          P43251                              Biotinidase                                    Extracellular
     17          P55290                              Cadherin-13                                      Membrane
     18          P27797                              Calreticulin                                     Cytoplasm
     19          O43852                               Calumenin                                       Cytoplasm
     20          P16870                           Carboxypeptidase E                                  Membrane
     21          P49747                  Cartilage oligomeric matrix protein                        Extracellular
     22          P07858                              Cathepsin B                                      Cytoplasm
     23          P07339                              Cathepsin D                                      Cytoplasm
     24          P43235                              Cathepsin K                                      Cytoplasm
     25          P07711                              Cathepsin L                                      Cytoplasm
     26          Q9UBR2                              Cathepsin Z                                      Cytoplasm
     27          P36222                       Chitinase-3-like protein 1                            Extracellular
     28          Q15782                       Chitinase-3-like protein 2                            Extracellular
     29          Q59FG9         Chondroitin sulfate proteoglycan 2 (versican) variant               Extracellular
     30          P10909                               Clusterin                                     Extracellular
     31          P02452                       Collagen alpha-1(I) chain                             Extracellular
     32          P02458                       Collagen alpha-1(II) chain                            Extracellular
     33          P02461                      Collagen alpha-1(III) chain                            Extracellular
     34          P02462                       Collagen alpha-1(IV) chain                            Extracellular
     35          P20908                       Collagen alpha-1(V) chain                             Extracellular
     36          P12109                       Collagen alpha-1(VI) chain                            Extracellular
     37          Q02388                      Collagen alpha-1(VII) chain                            Extracellular
     38          P12107                       Collagen alpha-1(XI) chain                            Extracellular
     39          Q99715                      Collagen alpha-1(XII) chain                            Extracellular
     40          P39059          Collagen alpha-1(XV) chain \[Contains: Endostatin\]                Extracellular
     41          P39060         Collagen alpha-1(XVIII) chain \[Contains: Endostatin\]              Extracellular
     42          P08123                       Collagen alpha-2(I) chain                             Extracellular
     43          P08572           Collagen alpha-2(IV) chain \[Contains: Canstatin\]                Extracellular
     44          P05997                       Collagen alpha-2(V) chain                             Extracellular
     45          P12110                       Collagen alpha-2(VI) chain                            Extracellular
     46          P25940                       Collagen alpha-3(V) chain                             Extracellular
     47          P12111                       Collagen alpha-3(VI) chain                            Extracellular
     48          P08253                      Collagenase (72 kDa type IV)                           Extracellular
     49          P00736                      Complement C1r subcomponent                            Extracellular
     50          P09871                      Complement C1s subcomponent                            Extracellular
     51          P01024                             Complement C3                                   Extracellular
     52          P29279                    Connective tissue growth factor                          Extracellular
     53          Q9Y240                C-type lectin domain family 11 member A                      Extracellular
     54          O75462                    Cytokine receptor-like factor 1                          Extracellular
     55          P07585                                Decorin                                      Extracellular
     56          Q07507                             Dermatopontin                                   Extracellular
     57          Q4VWZ6               Diazepam binding inhibitor, splice form 1c                      Cytoplasm
     58          Q9UBP4                       Dickkopf-related protein 3                            Extracellular
     59          Q14118                              Dystroglycan                                     Membrane
     60          Q13822           Ectonucleotide pyrophosphatase/phosphodiesterase 2                  Membrane
     61          Q12805       EGF-containing fibulin-like extracellular matrix protein 1            Extracellular
     62          O95967       EGF-containing fibulin-like extracellular matrix protein 2            Extracellular
     63          Q9Y6C2                                EMILIN-1                                     Extracellular
     64          Q9BXX0                                EMILIN-2                                     Extracellular
     65          P61916                    Epididymal secretory protein E1                          Extracellular
     66          Q9Y2E5                 Epididymis-specific alpha-mannosidase                         Cytoplasm
     67          Q16610                     Extracellular matrix protein 1                          Extracellular
     68          P08294              Extracellular superoxide dismutase \[Cu-Zn\]                   Extracellular
     69          P35555                              Fibrillin-1                                    Extracellular
     70          Q53TP5              Fibroblast activation protein, alpha subunit                     Cytoplasm
     71          Q06828                              Fibromodulin                                   Extracellular
     72          P02751                              Fibronectin                                      Membrane
     73          P23142                               Fibulin-1                                     Extracellular
     74          P98095                               Fibulin-2                                     Extracellular
     75          Q9UBX5                               Fibulin-5                                     Extracellular
     76          Q12841                     Follistatin-related protein 1                           Extracellular
     77          P16930                          Fumarylacetoacetase                                  Cytoplasm
     78          P09382                               Galectin-1                                    Extracellular
     79          Q08380                       Galectin-3-binding protein                              Membrane
     80          Q92820                        Gamma-glutamyl hydrolase                               Cytoplasm
     81          P06396                                Gelsolin                                     Extracellular
     82          Q9UJJ9               GlcNAc-1-phosphotransferase subunit gamma                       Cytoplasm
     83          P07093                           Glia-derived nexin                                Extracellular
     84          P04406                Glyceraldehyde-3-phosphate dehydrogenase                       Cytoplasm
     85          P35052                               Glypican-1                                      Membrane
     86          P28799                               Granulins                                     Extracellular
     87          Q14393                    Growth-arrest-specific protein 6                         Extracellular
     88          P00738                              Haptoglobin                                    Extracellular
     89          P00739                      Haptoglobin-related protein                            Extracellular
     90          O75629                          Human Protein CREG1                                   Nucleus
     91          P17936              Insulin-like growth factor-binding protein 3                   Extracellular
     92          P22692              Insulin-like growth factor-binding protein 4                   Extracellular
     93          P24592              Insulin-like growth factor-binding protein 6                   Extracellular
     94          Q16270              Insulin-like growth factor-binding protein 7                   Extracellular
     95          O95965                      Integrin beta-like protein 1                              Unknown
     96          P19823              Inter-alpha-trypsin inhibitor heavy chain H2                   Extracellular
     97          O14498                                  ISLR                                       Extracellular
     98          Q08431                              Lactadherin                                    Extracellular
     99          Q8NHP8                          LAMA-like protein 2                                Extracellular
     100         Q59H37                   Laminin alpha 2 subunit isoform b                         Extracellular
     101         Q16363                        Laminin subunit alpha-4                              Extracellular
     102         P07942                         Laminin subunit beta-1                              Extracellular
     103         P55268                         Laminin subunit beta-2                              Extracellular
     104         P11047                        Laminin subunit gamma-1                              Extracellular
     105         Q14767        Latent-transforming growth factor beta-binding protein 2             Extracellular
     106         Q99538                                Legumain                                       Cytoplasm
     107         Q07954           Low-density lipoprotein receptor-related protein 1                  Membrane
     108         P51884                                Lumican                                      Extracellular
     109         P10619                      Lysosomal protective protein                             Cytoplasm
     110         P13473              Lysosome-associated membrane glycoprotein 2                      Membrane
     111         Q9Y4K0                        Lysyl oxidase homolog 2                              Extracellular
     112         P09603                 Macrophage colony-stimulating factor 1                      Extracellular
     113         Q9UM22                 Mammalian ependymin-related protein 1                          Nucleus
     114         P48740                Mannan-binding lectin serine protease 1                      Extracellular
     115         P50281                      Matrix metalloproteinase-14                            Extracellular
     116         P01033                     Metalloproteinase inhibitor 1                           Extracellular
     117         P16035                     Metalloproteinase inhibitor 2                           Extracellular
     118         Q71SW6                        Muscle type neuropilin 1                               Membrane
     119         P14543                               Nidogen-1                                     Extracellular
     120         Q14112                               Nidogen-2                                     Extracellular
     121         Q02818                             Nucleobindin-1                                    Cytoplasm
     122         Q9NRN5                      Olfactomedin-like protein 3                            Extracellular
     123         Q86UD1                      Out at first protein homolog                              Unknown
     124         P26022                     Pentraxin-related protein PTX3                          Extracellular
     125         P62937                 Peptidyl-prolyl cis-trans isomerase A                         Cytoplasm
     126         P23284                       Peptidylprolyl isomerase B                              Cytoplasm
     127         Q15063                               Periostin                                     Extracellular
     128         P98160                                Perlecan                                       Membrane
     129         Q92626                          Peroxidasin homolog                                   Unknown
     130         P30086               Phosphatidylethanolamine-binding protein 1                      Cytoplasm
     131         P55058                     Phospholipid transfer protein                           Extracellular
     132         P36955                   Pigment epithelium-derived factor                         Extracellular
     133         Q9BTY2                       Plasma alpha-L-fucosidase                             Extracellular
     134         Q9Y646                   Plasma glutamate carboxypeptidase                         Extracellular
     135         P05155                      Plasma protease C1 inhibitor                           Extracellular
     136         P05121                   Plasminogen activator inhibitor 1                         Extracellular
     137         Q9GZP0                    Platelet-derived growth factor D                         Extracellular
     138         P07602            Proactivator polypeptide \[Contains: Saposin-A\]                 Extracellular
     139         Q15113                 Procollagen C-endopeptidase enhancer 1                      Extracellular
     140         Q02809           Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1                   Cytoplasm
     141         P07737                               Profilin-1                                      Cytoplasm
     142         P41222                      Prostaglandin-H2 D-isomerase                             Cytoplasm
     143         Q6UXB8                         Protease inhibitor 16                                 Membrane
     144         P07237                      Protein disulfide-isomerase                              Cytoplasm
     145         Q15084                     Protein disulfide-isomerase A6                            Cytoplasm
     146         P14618                     Pyruvate kinase isozymes M1/M2                            Cytoplasm
     147         Q96D15                            Reticulocalbin-3                                   Cytoplasm
     148         Q99969               Retinoic acid receptor responder protein 2                      Membrane
     149         O75326                             Semaphorin-7A                                     Membrane
     150         Q12884                                Seprase                                        Cytoplasm
     151         Q92743                         Serine protease HTRA1                               Extracellular
     152         P02787                            Serotransferrin                                  Extracellular
     153         P09486                                 SPARC                                       Extracellular
     154         Q9BUD6                               Spondin-2                                     Extracellular
     155         Q9BRK5                     Stromal cell-derived factor 4                             Cytoplasm
     156         O00391                          Sulfhydryl oxidase 1                                 Cytoplasm
     157         P00441                     Superoxide dismutase \[Cu-Zn\]                            Cytoplasm
     158         Q9Y490                                Talin-1                                        Membrane
     159         P24821                                Tenascin                                     Extracellular
     160         P22105                               Tenascin-X                                    Extracellular
     161         Q08629                               Testican-1                                    Extracellular
     162         P10599                              Thioredoxin                                      Cytoplasm
     163         Q16881                        Thioredoxin reductase 1                                Cytoplasm
     164         P07996                            Thrombospondin-1                                 Extracellular
     165         P35442                            Thrombospondin-2                                 Extracellular
     166         Q6FGX5                             TIMP1 protein                                   Extracellular
     167         Q15582         Transforming growth factor-beta-induced protein ig-h3               Extracellular
     168         O14773                        Tripeptidyl-peptidase 1                                Cytoplasm
     169         Q6EMK4                                Vasorin                                        Membrane
     170         P13611                         Versican core protein                               Extracellular
     171         P08670                                Vimentin                                       Cytoplasm
     172         P04004                              Vitronectin                                    Extracellular
     173         O76076               WNT1-inducible-signaling pathway protein 2                    Extracellular

^a^The subcellular location was determined for each protein based on the Ingenuity Pathway Analysis software (Ingenuity Systems).

![**The functional categories of the primary human adipocyte secretome.** The biological function analysis was determined for each protein based on the Ingenuity Pathway Analysis software (Ingenuity Systems).](1559-0275-11-20-3){#F3}

Quantification of the primary human adipocyte secretome
-------------------------------------------------------

Several mass spectrometry techniques can be used for quantitative analysis. Both isotopic and non-isotopic labeling are commonly used to provide quantitative analysis of proteins in complex protein samples \[[@B59]-[@B67]\]. For non-isotopic or label-free MS-based quantitative analysis, ion chromatogram intensity or observed peptide spectral counts are compared using quantitative software tools \[[@B68]-[@B76]\]. Peptide spectral counts quantification relies on the association between protein abundance and the number of MS/MS spectra identifying each protein. For this study, we used three biological replicates of conditioned media samples, which differed in complex proteome profiles and relative number of normalized spectral counts. For each of the biological replicates, prepared conditioned media from three treatment groups (LG, LG + PUG, HG + INS) was subjected to two technical replicates of reverse phase LC-MS/MS. All together, a total of 18 LC-MS/MS experiments were performed. SEQUEST was used to search MS data files from each LC-MS/MS run against a forward and reversed human database to calculate a FDR. ProteoIQ was used to cluster the peptides to their assigned proteins and to gather normalized spectral counts for proteins identified at less than a 1% FDR and assigned by at least two non-redundant peptides. Spectral counts were normalized for each technical replicate. For each biological replicate the normalized spectral counts were averaged followed and then the comparative ratios between the two insulin resistant conditions and the insulin responsive condition were calculated. Finally, the comparative ratios were averaged between all of the biological replicates. We set the threshold for reporting statistically significant differences at ≥150% (1.5-fold), an average of ≥5 total spectral counts, and an average of ≥3 normalized spectral counts for each treatment group. We identified 20 human adipocytokines whose secretion levels were upregulated and 4 proteins that were downregulated by at least 1.5-fold by the transition from the insulin sensitive condition to both insulin resistant conditions (Table [2](#T2){ref-type="table"}). We also identified 28 and 8 proteins that were upregulated or downregulated, respectively, in the transition from insulin sensitive to one of the insulin resistant conditions (Additional file [1](#S1){ref-type="supplementary-material"}: Table S2).

###### 

**Human adipocytokines regulated a minimum of 150% under both insulin resistant conditaions**^**a**^

   **No.**   **Protein ID**                **Identified proteins**                **LGPUG/LG**   **HGINS/LG**   **Ave. SC**   **SD**   **Ave. peptides**   **SD**
  --------- ---------------- --------------------------------------------------- -------------- -------------- ------------- -------- ------------------- --------
      1          Q96D15                       Reticulocalbin-3                        9.00           8.52          11.50       2.89          3.00           1.15
      2          Q9NRN5                  Olfactomedin-like protein 3                  5.40           7.57          13.60       6.31          3.00           0.00
      3          P09603            Macrophage colony-stimulating factor 1             2.98           5.02          5.00        1.87          1.60           0.55
      4          Q59H37               Laminin alpha 2 subunit isoform b               1.73           4.60          11.50       6.45          4.50           1.91
      5          Q15113            Procollagen C-endopeptidase enhancer 1             1.53           4.11          14.00       3.56          3.75           0.50
      6          Q07507                         Dermatopontin                         2.01           2.93          10.40       2.88          2.00           0.00
      7          Q02809       Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1       2.70           2.80          11.17       4.83          3.83           0.98
      8          P36222                  Chitinase-3-like protein 1                   1.49           2.68          26.00       8.05          6.33           0.52
      9          P05997                   Collagen alpha-2(V) chain                   1.55           2.44          9.33        2.89          2.67           0.58
     10          Q9Y240            C-type lectin domain family 11 member A            2.07           2.44          11.00       2.00          3.00           0.00
     11          Q06828                         Fibromodulin                          1.76           2.38          15.75       2.06          2.00           1.15
     12          O00391                     Sulfhydryl oxidase 1                      2.20           2.27          8.17        3.06          2.67           0.52
     13          P15144                       Aminopeptidase N                        2.19           2.03          22.00      13.34          4.33           1.86
     14          Q99538                           Legumain                            1.60           1.92          11.67       4.18          1.83           0.98
     15          Q6UXB8                     Protease inhibitor 16                     1.97           1.75          15.75       1.50          2.50           0.58
     16          P09486                             SPARC                             1.48           1.74         263.00      169.53         10.33          1.37
     17          P07942                    Laminin subunit beta-1                     1.48           1.69          63.67      13.34          16.83          1.72
     18          O75326                         Semaphorin-7A                         1.95           1.66          21.17       8.89          3.67           1.03
     19          P10909                           Clusterin                           1.77           1.63          17.00       6.39          3.17           0.75
     20          P24821                           Tenascin                            1.61           1.54          37.33       4.76          9.83           1.72
   **No.**   **Protein ID**                **Identified proteins**                **LG/LGPUG**   **LG/HGINS**   **Ave. SC**   **SD**   **Ave. peptides**   **SD**
      1          P61769                     Beta-2-microglobulin                      2.40           1.90          68.17      35.76          3.17           0.98
      2          P00739                  Haptoglobin-related protein                  1.87           1.66          5.67        0.58          2.00           0.00
      3          Q16270         Insulin-like growth factor-binding protein 7          1.75           1.59          19.00       9.76          4.33           1.03
      4          O95965                 Integrin beta-like protein 1                  1.68           1.57          9.00        1.41          3.00           0.00

^a^LGPUG: low glucose pluse PUGNAc; HGINS: high glucose pluse insulin as two insulin resistant conditions; Ave. SC: average total spectral count and SD: standard deviation.

To confirm the validity of the ratio that we used for statistical significance, we used the orthogonal method of immunoblotting. We confirmed that the regulation we observed in the proteomic experiment with immunoblotting for two proteins whose levels changed by only 1.5-fold in at least one of the insulin resistant conditions as determined by proteomics. In addition, we used cells where insulin resistance was induced using a more specific OGA inhibitor, GlcNAcstatin, to confirm the regulation we observed by using the less specific OGA inhibitor, PUGNAc \[[@B58],[@B77]\]. Figure [4](#F4){ref-type="fig"} shows that both SPARC and Chitinase-3-like protein 1 are upregulated in both insulin resistant conditions as determined by immunoblotting, which confirms our proteomic experiment.

![**Orthogonal validation of proteomic quantification.** Equal amounts of conditioned media from primary human adipocytes was immunoblotted with antibodies against SPARC or Chitinase-3-like protein 1.](1559-0275-11-20-4){#F4}

N-glycan site-mapping of the human adipocyte secretome
------------------------------------------------------

Many secreted proteins are modified by N-glycans. During disease states, the glycoforms of these proteins may change and have the potential to be used as disease biomarkers. Since the glycome of adipocytes is not well-defined, we determine sites of N-linked glycosylation on secreted adipocytokines as an initial step in biomarker discovery. The tryptic peptides generated from conditioned media were digested with PNGase F in the presence of ^18^O water to convert any N-glycan-modified Asp to an ^18^O-Asp residue. The resulting peptides were analyzed by LC-MS/MS using the previously described method for ITMS and the parent mass list method for FTMS as described in *Materials and Methods*. To obtain the parent mass list, the protein sequences of the 190 identified secreted proteins from Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Table S1 were extracted from the database. From these sequences, tryptic peptides, with allowance for two internal missed cleavage sites, that contained the consensus sequence, N-X-S/T, were obtained for theoretical mass calculations. Table [3](#T3){ref-type="table"} shows a total of 91 N-linked glycosylation sites that were identified on 52 proteins. These sites covered 10.3% of the theoretical 882 N-linked glycosylation site sequences generated from the secreted protein list.

###### 

**Identification of N-linked glycosylation sites using PNGase F with the incorporation of**^**18**^**O water in human adipocytokines**

   **No.**   **Protein ID**                    **Identifed proteins**                         **N-linked peptides**^**a**^
  --------- ---------------- ---------------------------------------------------------- ----------------------------------------
      1          P15144                           Aminopeptidase N                                   KLN\@YTLSQGHR
      2          P21810                               Biglycan                                      LLQVVYLHSNN\@ITK
      3          P16870                          Carboxypeptidase E                                 GN\@ETIVNLIHSTR
      4          P07339                             Cathepsin D                                       GSLSYLN\@VTR
      5          P43235                             Cathepsin K                                     SN\@DTLYIPEWEGR
      6          P07711                             Cathepsin L                                     YSVAN\@DTGFVDIPK
      7          P07711                             Cathepsin L                                   YSVAN\@DTGFVDIPKQEK
      8          P10909                              Clusterin                                      LAN\@LTQGEDQYYLR
      9          P02461                     Collagen alpha-1(III) chain                               ASQN\@ITYHCK
     10          P02461                     Collagen alpha-1(III) chain                  DGSPGGKGDRGEN\@GSPGAPGAPGHPGPPGPVGPAGK
     11          P20908                      Collagen alpha-1(V) chain                            VYCN\@FTAGGSTCVFPDKK
     12          P12109                      Collagen alpha-1(VI) chain                        ENYAELLEDAFLKN\@VTAQICIDKK
     13          P12109                      Collagen alpha-1(VI) chain                        GEDGPAGN\@GTEGFPGFPGYPGNR
     14          P12109                      Collagen alpha-1(VI) chain                              N\@FTAADWGQSR
     15          P12109                      Collagen alpha-1(VI) chain                              RN\@FTAADWGQSR
     16          Q02388                     Collagen alpha-1(VII) chain                        TAPEPVGRVSRLQILN\@ASSDVLR
     17          Q99715                     Collagen alpha-1(XII) chain                            EAGN\@ITTDGYEILGK
     18          P08123                      Collagen alpha-2(I) chain                             LLANYASQN\@ITYHCK
     19          P05997                      Collagen alpha-2(V) chain                               EASQN\@ITYICK
     20          P12111                      Collagen alpha-3(VI) chain                           GNPGEPGLN\@GTTGPKGIR
     21          P12111                      Collagen alpha-3(VI) chain                           GPPGVN\@GTQGFQGCPGQR
     22          P12111                      Collagen alpha-3(VI) chain                     GYPGDEGGPGERGPPGVN\@GTQGFQGCPGQR
     23          P09871                     Complement C1s subcomponent                    NCGVN\@CSGDVFTALIGEIASPNYPKPYPENSR
     24          O75462                   Cytokine receptor-like factor 1                        VLN\@ASTLALALANLN\@GSR
     25          O75462                   Cytokine receptor-like factor 1                            VVDDVSN\@QTSCR
     26          P07585                               Decorin                                 IADTN\@ITSIPQGLPPSLTELHLDGNK
     27          P07585                               Decorin                                  LGLSFNSISAVDN\@GSLANTPHLR
     28          Q9UBP4                      Dickkopf-related protein 3                              GSN\@GTICDNQR
     29          Q13822          Ectonucleotide pyrophosphatase/phosphodiesterase 2           AEGWEEGPPTVLSDSPWTN\@ISGSCK
     30          Q13822          Ectonucleotide pyrophosphatase/phosphodiesterase 2                   AIIAN\@LTCK
     31          Q9Y6C2                               EMILIN-1                                      LGALN\@SSLQLLEDR
     32          P35555                             Fibrillin-1                                     TAIFAFN\@ISHVSNK
     33          P02751                             Fibronectin                                  DQCIVDDITYNVN\@DTFHKR
     34          P02751                             Fibronectin                                   DQCIVDDITYNVN\@DTFHK
     35          P02751                             Fibronectin                                  LDAPTNLQFVN\@ETDSTVLVR
     36          Q12841                    Follistatin-related protein 1                              GSN\@YSEILDK
     37          Q12841                    Follistatin-related protein 1                            GSN\@YSEILDKYFK
     38          P09382                              Galectin-1                                     FNAHGDANTIVCNSK
     39          Q08380                      Galectin-3-binding protein                             ALGFEN\@ATQALGR
     40          Q08380                      Galectin-3-binding protein                              DAGVVCTN\@ETR
     41          Q08380                      Galectin-3-binding protein                            TVIRPFYLTN\@SSGVD
     42          P00738                             Haptoglobin                                    VVLHPN\@YSQVDIGLIK
     43          O75629                         Human Protein CREG1                                LN\@ITNIWVLDYFGGPK
     44          P17936             Insulin-like growth factor-binding protein 3                     GLCVN\@ASAVSR
     45          O14498                                 ISLR                                 SLDLSHNLISDFAWSDLHN\@LSALQLLK
     46          Q8NHP8                         LAMA-like protein 2                                SDLNPAN\@GSYPFKALR
     47          Q16363                       Laminin subunit alpha-4                             DAVRN\@LTEVVPQLLDQLR
     48          Q16363                       Laminin subunit alpha-4                         FYFGGSPISAQYAN\@FTGCISNAYFTR
     49          Q16363                       Laminin subunit alpha-4                                  LITEEAN\@R
     50          Q16363                       Laminin subunit alpha-4                          LTLSELDDIIKN\@ASGIYAEIDGAK
     51          Q16363                       Laminin subunit alpha-4                                RPASN\@VSASIQR
     52          P07942                        Laminin subunit beta-1                               LSDTTSQSN\@STAK
     53          P11047                       Laminin subunit gamma-1                                VN\@NTLSSQISR
     54          P11047                       Laminin subunit gamma-1                               KYEQAKN\@ISQDLEK
     55          P11047                       Laminin subunit gamma-1                                 LLNN\@LTSIK
     56          P11047                       Laminin subunit gamma-1                              TAN\@DTSTEAYNLLLR
     57          P11047                       Laminin subunit gamma-1                             TLAGEN\@QTAFEIEELNR
     58          P11047                       Laminin subunit gamma-1                               VNDN\@KTAAEEALR
     59          Q14767       Latent-transforming growth factor beta-binding protein 2         DGTQQAVPLEHPSSPWGLN\@LTEK
     60          P51884                               Lumican                                   AFEN\@VTDLQWLILDHNLLENSK
     61          P51884                               Lumican                                    LGSFEGLVN\@LTFIHLQHNR
     62          P51884                               Lumican                                     LHINHNN\@LTESVGPLPK
     63          P13473             Lysosome-associated membrane glycoprotein 2                   IAVQFGPGFSWIAN\@FTK
     64          P01033                    Metalloproteinase inhibitor 1                          AKFVGTPEVN\@QTTLYQR
     65          P01033                    Metalloproteinase inhibitor 1                           FVGTPEVN\@QTTLYQR
     66          P01033                    Metalloproteinase inhibitor 1                            SHN\@RSEEFLIAGK
     67          Q9NRN5                     Olfactomedin-like protein 3                           IYVLDGTQN\@DTAFVFPR
     68          P26022                    Pentraxin-related protein PTX3                              ATDVLN\@K
     69          Q15063                              Periostin                                       EVN\@DTLLVNELK
     70          Q15063                              Periostin                                     IFLKEVN\@DTLLVNELK
     71          P98160                               Perlecan                                  SLTQGSLIVGDLAPVN\@GTSQGK
     72          P55058                    Phospholipid transfer protein                             VSN\@VSCQASVSR
     73          P36955                  Pigment epithelium-derived factor                      VTQN\@LTLIEESLTSEFIHDIDR
     74          P36955                  Pigment epithelium-derived factor                    VTQN\@LTLIEESLTSEFIHDIDRELK
     75          P05155                     Plasma protease C1 inhibitor                        VGQLQLSHN\@LSLVILVPQNLK
     76          P05155                     Plasma protease C1 inhibitor                         VLSN\@NSDANLELINTWVAK
     77          P07602           Proactivator polypeptide \[Contains: Saposin-A\]                  TN\@STFVQALVEHVK
     78          P07602           Proactivator polypeptide \[Contains: Saposin-A\]                    LIDNN\@KTEK
     79          P07602           Proactivator polypeptide \[Contains: Saposin-A\]                LIDNN\@KTEKEILDAFDK
     80          P07602           Proactivator polypeptide \[Contains: Saposin-A\]                     NLEKN\@STK
     81          P07602           Proactivator polypeptide \[Contains: Saposin-A\]                NLEKN\@STKQEILAALEK
     82          P07602           Proactivator polypeptide \[Contains: Saposin-A\]               TN\@STFVQALVEHVKEECDR
     83          P09486                                SPARC                                           VCSNDN\@K
     84          P09486                                SPARC                                     VCSNDN\@KTFDSSCHFFATK
     85          P24821                               Tenascin                                         N\@TTSYVLR
     86          P24821                               Tenascin                                    LN\@YSLPTGQWVGVQLPR
     87          P07996                           Thrombospondin-1                                  VVN\@STTGPGEHLR
     88          P35442                           Thrombospondin-2                                  VVN\@STTGTGEHLR
     89          Q6FGX5                            TIMP1 protein                                   FVGTPEVN\@QTTLYQR
     90          Q6FGX5                            TIMP1 protein                                    SHN\@RSEEFLIAGK
     91          Q6EMK4                               Vasorin                                         LHEITN\@ETFR

^a^An @ indicates the site of N-linked glycosylation.

Characterization of the human adipocyte glycome
-----------------------------------------------

To better define the glycome of human adipocytes, we performed N-linked and O-linked glycan analysis using mass spectrometry. Glycans were released from whole-cell human adipocyte extracts by PNGase F for N-linked glycans and by β-elimination for O-linked glycans as shown in Figure [2](#F2){ref-type="fig"}C. Figure [5](#F5){ref-type="fig"}A shows that the permethylated N-linked glycans were characterized by full FTMS spectrum using a LTQ Orbitrap XL *(left panel, top)* followed by MS/MS fragmentation by TIM analysis in the ion trap *(left panel, bottom)*. The fragmentation of a biantennary N-linked glycan is shown as an example. We used the GlycoWorkbench to manually interpret a total of 155 N-linked glycan structures from MS/MS spectra at different charge states as shown in Additional file [1](#S1){ref-type="supplementary-material"}: Table S3. In Figure [5](#F5){ref-type="fig"}A *(right panel)*, we show that 28 of the predominant N-linked glycans are assigned to a full FTMS and a MS/MS spectrum.

![**Characterization of the primary human adipocyte glycome by MS/MS and TIM scan. (A)** Upper left panel: a full FTMS spectrum of the N-linked glycan mixture, lower left panel: the characterization of a biantennary complex N-linked glycan structure by MS/MS fragmentation, right panel: a list of predominant N-linked glycans. **(B)** Upper left panel: a full FTMS spectrum of the O-linked glycan mixture, upper right panel: the characterization of a core 2 O-linked glycan structure by MS/MS fragmentation, lower panel: a list of predominant O-linked glycans. (pink star): Xyl, (red inverted triangle): Fuc, (blue circle): Glc, (green circle): Man, (yellow circle): Gal, (blue square): GlcNAc, (yellow square): GalNAc, and (violet diamond): NeuAc.](1559-0275-11-20-5){#F5}

Figure [5](#F5){ref-type="fig"}B *(left panel)* shows a full FTMS spectrum from an O-linked glycan mixture. 10 of the predominant O-linked glycans were assigned from the full FTMS spectra (Figure [5](#F5){ref-type="fig"}B, *bottom panel*). A representative fragmentation spectrum is shown for one of the core 2 O-linked glycans (Figure [5](#F5){ref-type="fig"}B, *right panel*). A total of 29 O-linked glycans were characterized from MS/MS spectra at singly and doubly charged states as shown in Additional file [1](#S1){ref-type="supplementary-material"}: Table S4.

Relative quantification of the human adipocyte glycome upon the induction of insulin resistance using ^13^C labeling and prevalence
-----------------------------------------------------------------------------------------------------------------------------------

For the comparative quantification of glycans, we performed isotopic labeling using heavy/light iodomethane (^13^CH~3~I and ^12^CH~3~I) \[[@B78],[@B79]\]. The ^13^C/^12^C ratio from the sum of the peak areas and the prevalence ratio between the different treatment conditions were used for relative quantification. Permethylated glycans were mixed in a 1:1 protein ratio and analyzed in quadruplicate using an LTQ Orbitrap XL. Figure [6](#F6){ref-type="fig"}A (*left panel*) shows the isotopic pairs of N-linked glycans on a full FTMS spectrum. Figure [6](#F6){ref-type="fig"}A (*right panel*) shows an example of a calculated ^13^C/^12^C ratio from sum of peak area between LG + PUGNAc (LGPUG) and LG conditions. Additional file [1](#S1){ref-type="supplementary-material"}: Table S5 shows a total of 48 N-linked glycans that were relatively quantified between the insulin resistant conditions (LGPUG and HGINS) and insulin responsive condition (LG) by the average ^13^C/^12^C ratio and the average prevalence ratio. This approach simultaneously quantified a broad range of N-glycan structures in a complex mixture; however we did not observe highly significant changes in N-glycan ^13^C/^12^C ratios or prevalence ratios. Figure [6](#F6){ref-type="fig"}B (*left panel*) shows the isotopic pairs of O-linked glycans on a full FTMS spectrum. Figure [6](#F6){ref-type="fig"}B (*right panel*) shows an example of the calculated ^13^C/^12^C ratio from the sum of peak areas between LGPUG and LG conditions. Additional file [1](#S1){ref-type="supplementary-material"}: Table S6 shows a total of 12 O-linked glycans that were relatively quantified between insulin resistant and insulin sensitive conditions. We did not observe highly significant changes in O-glycan ^13^C/^12^C ratios or prevalence ratios.

![**Relative quantification of the primary human adipocytes glycome during insulin resistance using**^**13**^**C/**^**12**^**C labeling. (A)** Upper left panel: a full FTMS spectrum of ^13^C/^12^C labeled N-linked glycans in HGINS and LG, upper right panel: a FTMS spectrum to calculate ^13^C/^12^C ratios from the sum of isotopic peak areas between the isotopic pairs, lower panel: a list of relative ratios for HGINS and LG for predominant N-linked glycans. **(B)** Upper left panel: a full FTMS spectrum of ^13^C/^12^C labeled O-linked glycans in LGPUG and LG, upper right panel: a FTMS spectrum to calculate ^13^C/^12^C ratios from the sum of isotopic peak areas between the isotopic pairs, lower panel: a list of relative ratios for LGPUG and LG for predominant O-linked glycans.](1559-0275-11-20-6){#F6}

Discussion
==========

Several groups have reported the rodent adipocyte secretome during insulin resistance, but there have been fewer such studies performed with human adipocytes \[[@B25],[@B80]-[@B82]\]. It is advantageous to investigate the secretome of human adipose tissue because there are bound to be differences between the rodent and human secretome \[[@B8]\]. The differences in the secretome of human adipose tissue have been investigated during adipogenesis and between different fat pad depots \[[@B83]-[@B86]\]. Other studies have characterized the secretome without quantification \[[@B87],[@B88]\]. Another approach has been to study a limited list of known adipocytokines during insulin sensitivity and insulin resistance \[[@B89],[@B90]\]. Therefore, our study fills an important gap in the literature by taking a discovery approach to characterizing and quantifying the human adipocyte secretome in both insulin sensitive and two different insulin resistance conditions. In addition, we characterize and quantify the glycome of human adipocytes, which has not been described to our knowledge.

We report a total of 193 secreted proteins from human adipocytes (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). Using Ingenuity Pathways Analysis we determined that many of the secreted proteins were enzymes, peptidases, or other functions (Figure [3](#F3){ref-type="fig"}). The largest pool of identified proteins from the other category corresponds to extracellular matrix proteins. A common theme among the adipose tissue secretome studies is that extracellular matrix (ECM) proteins, ECM remodelers, inflammatory, and angiogenesis proteins are highly represented \[[@B7],[@B81],[@B87],[@B91]\]. The accumulation of fat mass during obesity requires extensive tissue remodeling that is accomplished by ECM remodelers. The remodeling can generate an inflammatory response during obesity and insulin resistance due to limited angiogenesis, localized hypoxia, adipocyte necrosis, increased fibrosis, altered adipocytokine secretion, and M1-stage macrophage and other immune cell infiltration \[[@B4],[@B92]-[@B96]\]. Many of the adipocytokines we identified, such as SPARC and Chitinase-3-like protein 1, have been implicated in inflammation \[[@B97],[@B98]\]. In addition, tissue remodeling requires extensive crosstalk between the different cell types that comprise adipose tissue. Several of the adipocytokines we identified, such as Gelsolin, Calreticulin, and Cathepsin D, may be expressed in cell types other than adipocytes \[[@B87],[@B99]\]. By using primary adipocytes instead of a cell line, the secretome we identified better represents the physiological status of adipose tissue. In the future, these identified adipocytokines may potentially be used as prognostic/diagnostic biomarkers for metabolic syndrome, T2DM, and other complications.

We generated insulin resistance in the human adipocytes by both directly and indirectly modulating O-GlcNAc levels. The elevation of O-GlcNAc levels has been shown to be sufficient to induce insulin resistance in many systems \[[@B19]-[@B24]\]. We have previously demonstrated that the induction of insulin resistance in this way in rodent adipocytes alters the secretion of several adipocytokines \[[@B25]\]. Here, we showed that 20 and 4 adipocytokines were upregulated or downregulated, respectively, upon the transition to insulin resistance by both directly and indirectly modulating O-GlcNAc levels (Table [2](#T2){ref-type="table"}). We also identified 28 and 8 adipocytokines that were upregulated or downregulated, respectively, upon the induction of insulin resistance by one of the two methods (Additional file [1](#S1){ref-type="supplementary-material"}: Table S2). In this study, we find that Sulfhydryl oxidase 1 (Quiescin Q6), laminin B1, and Chitinase-3-like protein 1 are upregulated during both insulin resistant conditions, which was also observed in the rodent study. SPARC was upregulated in both insulin resistant conditions in human adipocytes and was found to be upregulated in HG + INS in rodent adipocytes by proteomics. Four other proteins were observed to be regulated by insulin resistance in both rodent and human adipocytes; however, the regulation was slightly different between species. Thioredoxin was downregulated in both insulin resistant conditions in rodent adipocytes and during HG + INS in human adipocytes but was upregulated during LG + PUG in human adipocytes. Gelsolin was upregulated in both insulin resistant conditions in rodent adipocytes and during HG + INS in human adipocytes but was not regulated by LG + PUG. Fibulin 2 was downregulated in both insulin resistant conditions in rodent adipocytes but was not regulated or upregulated in LG + PUG and HG + INS, respectively, in human adipocytes. From these examples, it is clear that there are differences in adipocytokine secretion between rodents and humans. Because the proteome sample is extremely complex, we may not have achieved sufficient resolution to quantify some of the proteins that were observed in both rodent and human adipocyte secretomes, such as Angiotensinogen, Cathepsin B, and Spondin 1 \[[@B25],[@B100]\]. Because we assigned significance to a relatively small fold change (1.5 fold) for quantification, we verified the regulation of two adipocytokines that changed by 1.5 fold by an independent, orthogonal method. Both SPARC and Chitinase-3-like protein 1 protein levels were altered in a similar manner as measured by both quantitative proteomics and immunoblotting (Figure [4](#F4){ref-type="fig"}). In addition, the regulation of these proteins by O-GlcNAc was verified using a more OGA-specific N-acetyglucosaminidase inhibitor, GlcNAcstatin.

The inclusion of an insulin resistance condition generated by directly modulating O-GlcNAc levels in our proteomic study helped us to better define the proteins regulated by O-GlcNAc in human adipocytes. The O-GlcNAc modification is found on hundreds in nucleocytosolic proteins and can affect protein function in diverse ways, such as protein-protein interactions, protein degradation, interplay with phosphorylation, localization, and transcriptional activation \[[@B101]\]. Compiling a list of proteins modulated by O-GlcNAc is the first step in understanding the mechanism of how O-GlcNAc affects adipocytokine expression. We have used the data generated by our previous rodent proteomic study to investigate the transcriptional regulation of adipocytokines by global O-GlcNAc levels (unpublished data). Although several studies have associated elevated O-GlcNAc levels with adipocytokine expression, no specific molecular mechanism has been reported \[[@B13]-[@B16],[@B21],[@B102],[@B103]\].

We also characterize the N-linked and O-linked glycome for human adipocytes. Glycosylation and other PTM's provide an additional layer of regulatory complexity to expressed proteins. To understand the full functionality of a protein, one must know the state of the PTM's. Since secretory proteins, such as adipocytokines, are exposed to the glycosylation machinery that reside in the ER and Golgi apparatus as they make their way through the secretory pathway, they often have a high degree of complex glycosylation. The subset of glycans expressed by cells depends on multiple factors, such as developmental stage, tissue type, and the genetic and physiological state of the cell. It is not known whether adipocytes change glycan expression patterns in response to insulin resistance. Since glycosylation can affect diverse processes that are relevant to adipose tissue remodeling in obesity, such as cell-cell interactions, growth factor sequestration, cytokine activation, and cell migration, there is a need to define the adipocyte glycome \[[@B34],[@B104],[@B105]\].

Characterizing the glycome poses many challenges because there is no template for modification, as in DNA, and there is an incredible diversity of glycoforms. Mass spectrometry can provide both structural and abundance information using a small amount of material from a relatively complex mixture \[[@B106]\]. However, it is still difficult to assign specific glycoforms to specific protein residues in a complex mixture. To determine sites of N-glycosylation on the secreted proteins, we used PNGase F and ^18^O water to convert the glycan-modified Asn to an ^18^O-Asp residue, thereby leaving a chemical marker of the glycosylation site. We identified 91 sites on 51 proteins of N-linked glycosylation by Orbitrap mass spectrometer using the parent mass list obtained from theoretical consensus sequence in the secretome list (Table [3](#T3){ref-type="table"}). For relative glycan quantification, we permethylated using heavy or light iodomethane (^13^CH~3~I and ^12^CH~3~I) and used prevalence data. The use of isotopic labels allows for mixing of the samples to be compared before analysis, thus providing an internal standard and preventing run to run technical variation \[[@B49],[@B78]\]. These techniques allow us to determine the full diversity and changes in major and minor adipocyte glycans during insulin sensitive and resistant conditions. We characterized a total of 155 N-linked glycans and 29 of O-linked glycans (Figure [5](#F5){ref-type="fig"}, Additional file [1](#S1){ref-type="supplementary-material"}: Table S3, Table S4). The results presented here demonstrate that the human adipocytes are expressing extended hybrid and complex N-linked glycans, in addition to high mannose glycans. Adipose tissues possess the biosynthetic ability to generate diverse O-linked glycans such as core structure, O-glucose glycans, and O-fucose glycans.

Following characterization, we determined the change in glycan prevalence during insulin resistance using isotopic and prevalence ratios. We quantified 48 N-linked glycans and 12 O-linked glycans (Figure [6](#F6){ref-type="fig"}, Additional file [1](#S1){ref-type="supplementary-material"}: Tables S5-S6). Our results showed that changes of glycan prevalence were not statistically different between the insulin sensitive and insulin resistant conditions. It has been suggested that altering the intracellular UDP-GlcNAc pool, such as during increased glucose flux, changes the degree of N-glycan branching in an ultrasensitive manner \[[@B37]\]. While it is clear that the induction of insulin resistance in adipocytes massively upregulates intracellular glycosylation (Figure [1](#F1){ref-type="fig"}), we did not observe significant changes in complex glycosylation. This suggests that changes in complex glycosylation are not necessary for the induction of insulin resistance; although we cannot rule out that they play a role in insulin resistance that occurs over a long period of time. Since insulin resistance was generated by treatment for 40 hours, it is possible that the changes in glycan structure had not had time to significantly change.

In conclusion, we have characterized the secretome and glycome of primary human adipocytes during insulin resistance using a proteomic approach. We generated insulin resistance by either directly or indirectly modulating O-GlcNAc levels, which provides a list of adipocytokines that are modulated by O-GlcNAc levels. Adipocytokine and glycan levels were quantified between insulin sensitive and insulin resistant conditions and sites of N-glycosylation were identified. This study helps to define the secretome of primary human adipocytes during insulin resistance and helps to characterize and quantify the previously unknown primary adipocyte glycome. Finally, while elevated glucose levels and flux through the hexosamine pathway could theoretically alter both complex glycosylation and O-GlcNAc levels, our findings clearly demonstrate, under the short time frame used here where significant changes were observed in adipocytokine secretion but not in complex glycosylation, that only elevation in O-GlcNAc levels correlate with the observed changes in adipocytokine secretion.
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